menu
    • menu
    [{"orgOrder":0,"company":"Forward Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Forward Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Forward Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Forward Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Forward Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"FT2109","moa":"TNFR1 signaling","graph1":"Immunology","graph2":"Phase I","graph3":"Forward Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forward Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Forward Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Forward Therapeutics

    Menu

    Forward Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Forward Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Forward Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FT2109

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Forward Therapeutics Doses First Participants in Phase 1 Study of FT2109, a TNF Inhibitor

                            Details : FT2109, a miscellaneous product targeting TNFR1 signaling, shows promise in treating chronic inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2025

                            Lead Product(s) : FT2109

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Forward Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed

                            Forward Therapeutics

                            U.S.A arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : RA Capital Management

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune...

                            Details : The net proceeds will be used to advance company's portfolio of novel, next-generation, small molecule therapies for chronic immunological and inflammatory disorders, towards clinical development.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 08, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : RA Capital Management

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth